<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESTAZOLAM</span><br/>(es-ta-zo'lam)<br/><span class="topboxtradename">Prosom<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">benzodiazepine</span><br/><b>Prototype: </b>Lorazepam<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Benzodiazepine whose effects (anxiolytic, sedative, hypnotic, skeletal muscle relaxant) are mediated by the inhibitory neurotransmitter
         gamma-aminobutyric acid (GABA). GABA acts at the thalamic, hypothalamic, and limbic levels of CNS.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Benzodiazepines generally decrease the number of awakenings from sleep. Stage 2 (unequivocal sleep) is increased with all
         benzodiazepines. Estazolam shortens stages 3 and 4 (slow-wave sleep), and REM sleep is shortened. The total sleep time, however,
         is increased with estazolam.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of insomnia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known sensitivity to benzodiazepines; acute closed-angle glaucoma, primary depressive disorders or psychosis; abrupt discontinuation;
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and hepatic impairment, renal failure; organic brain syndrome, alcoholism, benzodiazepine dependence, suicidal ideations,
         CNS depression, seizure disorder, status epilepticus; substance abuse; shock, coma; dementia, mania, psychosis; myasthenia
         gravis, Parkinson's disease; sleep apnea; open-angle glaucoma, GI disorders, older adult and debilitated patients; limited
         pulmonary reserve, pulmonary disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Insomnia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg h.s. may increase up to 2 mg if necessary (some debilitated older adult patients should start with 0.5 mg h.s.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>For older adult patients in good health, a 1-mg dose is indicated; reduce initial dose to 0.5 mg for debilitated or small
            older adult patients.
         </li>
<li>Dosage reduction also may be needed in the presence of hepatic impairment.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, impaired coordination, hypokinesia, <span class="speceff-common">somnolence,</span> hangover, weakness.  <span class="typehead">CV:</span> Palpitations, arrhythmias, syncope (all rare). <span class="typehead">Hematologic:</span> Leukopenia, <span class="speceff-life">agranulocytosis</span>. <span class="typehead">GI:</span> Constipation, xerostomia, anorexia, flatulence, vomiting. <span class="typehead">Musculoskeletal:</span> Arthritis, arthralgia, myalgia, muscle spasm. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cimetidine</b> may decrease metabolism of estazolam and increase its effects; <b>alcohol</b> and other <span class="classification">cns depressants</span> may increase drowsiness; CYP3A4 inhibitors <b>(ketoconazole, itraconazole, nefazodone, diltiazem, fluvoxamine, cimetidine, isoniazid, erythromycin)</b> can increase concentrations and toxicity of estazolam; <b>carbamazepine, phenytoin, rifampin,</b>
<span class="classification">barbiturates</span> may decrease estazolam concentrations. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> &gt;1 quart may increase toxicity. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Onset:</span> 2030 min. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Crosses rapidly into brain; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1024 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for improvement in S&amp;S of insomnia.</li>
<li>Assess for excess CNS depression or daytime sedation.</li>
<li>Assess for safety, especially with older adult or debilitated patients, as dizziness and impaired coordination are known adverse
            effects.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn adverse effects and report those experienced to the physician.</li>
<li>Avoid using this drug in combination with other CNS depressant drugs or alcohol.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>